{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:13:06Z","timestamp":1771661586239,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/bf03325638","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T02:07:44Z","timestamp":1377828464000},"page":"13-23","source":"Crossref","is-referenced-by-count":22,"title":["Infliximab in Psoriasis and Psoriatic Arthritis"],"prefix":"10.1007","volume":"27","author":[{"given":"Marina","family":"Papoutsaki","sequence":"first","affiliation":[]},{"given":"Filipa","family":"Os\u00f3rio","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Magina","sequence":"additional","affiliation":[]},{"given":"Sergio","family":"Chimenti","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,8,29]]},"reference":[{"issue":"5","key":"BF03325638_CR1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826\u201350","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"BF03325638_CR2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2133.1996.tb03826.x","volume":"135","author":"GJ Nevitt","year":"1996","unstructured":"Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients\u2019 beliefs and attitudes towards the disease. Br J Dermatol 1996; 135(4): 533\u20137","journal-title":"Br J Dermatol"},{"issue":"4","key":"BF03325638_CR3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000119415","volume":"216","author":"M Augustin","year":"2008","unstructured":"Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216(4): 366\u201372","journal-title":"Dermatology"},{"issue":"2","key":"BF03325638_CR4","first-page":"14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii14\u201317","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"BF03325638_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58(5): 851\u201364","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"BF03325638_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","volume":"57","author":"MM Jiaravuthisan","year":"2007","unstructured":"Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57(1): 1\u201327","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"BF03325638_CR7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","volume":"43","author":"L Williamson","year":"2004","unstructured":"Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis-clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43(6): 790\u20134","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"BF03325638_CR8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1529-8019.2007.00112.x","volume":"20","author":"M Lawry","year":"2007","unstructured":"Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20(1): 60\u20137","journal-title":"Dermatol Ther"},{"issue":"2","key":"BF03325638_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","volume":"221","author":"K Reich","year":"2010","unstructured":"Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221(2): 172\u20138","journal-title":"Dermatology"},{"issue":"3","key":"BF03325638_CR10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","volume":"163","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163(3): 580\u20135","journal-title":"Br J Dermatol"},{"issue":"1","key":"BF03325638_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000316169","volume":"221","author":"R Baran","year":"2010","unstructured":"Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221 Suppl 1:1\u20135","journal-title":"Dermatology"},{"issue":"1","key":"BF03325638_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000316179","volume":"221","author":"RG Langley","year":"2010","unstructured":"Langley RG, Dauden E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010; 221 Suppl 1: 29\u201342","journal-title":"Dermatology"},{"key":"BF03325638_CR13","doi-asserted-by":"crossref","unstructured":"Papoutsaki M, Costanzo A. Diagnosis and treatment of psoriasis and psoriatic arthritis. BioDrugs 2012; Citation to be confirmed at publication","DOI":"10.1007\/BF03325637"},{"key":"BF03325638_CR14","unstructured":"Centocor Ortho Biotech Inc. Remicade(RM) (infliximab) for IV injection. [Online] 2009; Available from: http:\/\/www.remicade.com\/remicade\/assets\/ HCP_PPI.pdf"},{"key":"BF03325638_CR15","unstructured":"Electronic Medicines Compendium. Remicade 100mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Schering- Plough Ltd. [Online] 2010; Available from: http:\/\/www.medicines.org.uk\/emc\/document.aspx?documentId=3236"},{"issue":"9494","key":"BF03325638_CR16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494): 1367\u201374","journal-title":"Lancet"},{"issue":"1","key":"BF03325638_CR17","doi-asserted-by":"crossref","first-page":"31e1","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(1): 31e1\u201315","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"BF03325638_CR18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo- controlled trial. J Am Acad Dermatol 2004; 51(4): 534\u201342","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"BF03325638_CR19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","volume":"154","author":"K Reich","year":"2006","unstructured":"Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154(6): 1161\u20138","journal-title":"Br J Dermatol"},{"issue":"3","key":"BF03325638_CR20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","volume":"159","author":"SR Feldman","year":"2008","unstructured":"Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate- to-severe psoriasis. Br J Dermatol 2008; 159(3): 704\u201310","journal-title":"Br J Dermatol"},{"issue":"4","key":"BF03325638_CR21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4): 1227\u201336","journal-title":"Arthritis Rheum"},{"issue":"8","key":"BF03325638_CR22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64(8): 1150\u20137","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"BF03325638_CR23","first-page":"869","volume":"35","author":"CE Antoni","year":"2008","unstructured":"Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35(5): 869\u201376","journal-title":"J Rheumatol"},{"issue":"4","key":"BF03325638_CR24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66(4): 498\u2013505","journal-title":"Ann Rheum Dis"},{"issue":"31","key":"BF03325638_CR25","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta10310","volume":"10","author":"N Woolacott","year":"2006","unstructured":"Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006; 10(31): iii\u2013iv, xiii-xvi, 1-239","journal-title":"Health Technol Assess"},{"issue":"4","key":"BF03325638_CR26","first-page":"14","volume":"5","author":"AL Tan","year":"2008","unstructured":"Tan AL, Rhodes LA, Marzo-Ortega H, et al. What imaging has told us about psoriatic arthritis. Rheumatology in Practice 2008; 5(4): 14\u201316","journal-title":"Rheumatology in Practice"},{"issue":"4","key":"BF03325638_CR27","first-page":"159","volume":"27","author":"LG Filippis De","year":"2005","unstructured":"De Filippis LG, Caliri A, Lo Gullo R, et al. Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. Int J Tissue React 2005; 27(4): 159\u201362","journal-title":"Int J Tissue React"},{"issue":"2","key":"BF03325638_CR28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","volume":"49","author":"P Rich","year":"2003","unstructured":"Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49(2): 206\u201312","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"BF03325638_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7750.2008.08012","volume":"13","author":"K Noiles","year":"2009","unstructured":"Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13(1): 1\u20135","journal-title":"J Cutan Med Surg"},{"key":"BF03325638_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-3083.2009.03364.x","volume":"23","author":"K Reich","year":"2009","unstructured":"Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 Suppl 1: 15\u201321","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"BF03325638_CR31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2004.09.012","volume":"52","author":"L Bianchi","year":"2005","unstructured":"Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52(4): 736\u20137","journal-title":"J Am Acad Dermatol"},{"key":"BF03325638_CR32","doi-asserted-by":"crossref","unstructured":"Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2011; DOI: 10.1136\/ard.2011.150995","DOI":"10.1136\/ard.2011.150995"},{"issue":"8","key":"BF03325638_CR33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","volume":"37","author":"E Adisen","year":"2010","unstructured":"Adisen E, Aral A, Aybay C, et al. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol 2010; 37(8): 708\u201313","journal-title":"J Dermatol"},{"issue":"4","key":"BF03325638_CR34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","volume":"46","author":"CH Roux","year":"2007","unstructured":"Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46(4): 695\u20138","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"BF03325638_CR35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000262284","volume":"220","author":"L Puig","year":"2010","unstructured":"Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220(1): 71\u20136","journal-title":"Dermatology"},{"issue":"2","key":"BF03325638_CR36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000111512","volume":"216","author":"AD Cohen","year":"2008","unstructured":"Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216(2): 152\u20135","journal-title":"Dermatology"},{"issue":"4","key":"BF03325638_CR37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.phrs.2008.02.006","volume":"57","author":"R Saraceno","year":"2008","unstructured":"Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57(4): 290\u20135","journal-title":"Pharmacol Res"},{"issue":"5","key":"BF03325638_CR38","first-page":"855","volume":"35","author":"K Briot","year":"2008","unstructured":"Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35(5): 855\u201361","journal-title":"J Rheumatol"},{"issue":"2","key":"BF03325638_CR39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000182250","volume":"218","author":"D McGonagle","year":"2009","unstructured":"McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal append- age-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218(2): 97\u2013102","journal-title":"Dermatology"},{"issue":"2","key":"BF03325638_CR40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/rheumatology\/kel214","volume":"46","author":"AL Tan","year":"2007","unstructured":"Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology (Ox- ford) 2007; 46(2): 253\u20136","journal-title":"Rheumatology (Ox- ford)"},{"issue":"3","key":"BF03325638_CR41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.det.2006.03.014","volume":"24","author":"X Wortsman","year":"2006","unstructured":"Wortsman X, Jemec GB. Ultrasound imaging of nails. Dermatol Clin 2006; 24(3): 323\u20138","journal-title":"Dermatol Clin"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03325638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03325638\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03325638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T03:45:23Z","timestamp":1646451923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03325638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":41,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BF03325638"],"URL":"https:\/\/doi.org\/10.1007\/bf03325638","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}